Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-centric biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. The cornerstone of the Amicus portfolio is Galafold, an oral precision medicine for people living with Fabry disease who have amenable GLA variants. The lead biologics program in the Amicus Therapeutics pipeline is AT-GAA, an investigational therapy for Pompe disease. Amicus Therapeutics is committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for rare metabolic diseases. Source
No articles found.
A patient that is diagnosed with cancer today will have a genetic screen on their ...
A patient that is diagnosed with cancer today w...
Bio-Path is a biotechnology company developing targeted therapies for acute myeloi...
Bio-Path is a biotechnology company developing ...
Aytu is committed to better health for men and women here at home and worldwide. W...
Aytu is committed to better health for men and ...
Arbutus Biopharma is a publicly-traded (NASDAQ:ABUS) biopharmaceutical company ded...
Arbutus Biopharma is a publicly-traded (NASDAQ:...
Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company focused on...
Deciphera Pharmaceuticals is a clinical-stage b...
Ardelyx is focused on enhancing the way people with cardiorenal diseases are treat...
Ardelyx is focused on enhancing the way people ...
PTC is a science-led, global biopharmaceutical company focused on the discovery, d...
PTC is a science-led, global biopharmaceutical ...
Join the National Investor Network and get the latest information with your interests in mind.